Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ONO Pharmaceutical Co ( (JP:4528) ) has provided an announcement.
ONO Pharmaceutical Co., Ltd. released supplementary materials for its fiscal year 2025 consolidated financial results on a core basis, covering the period from April 1, 2025 to March 31, 2026. The materials outline sales revenue for major products and geographic segments, a reconciliation between full and core results, and key metrics such as depreciation, capital expenditure and employee numbers.
The company also provided a consolidated financial forecast for fiscal year 2026, including projected sales by product and region and details on capital and intangible asset investments. Additional sections highlight the status of shares and give an overview of ONO’s development pipeline and main development projects, signaling continued focus on R&D and potential future product launches.
The most recent analyst rating on (JP:4528) stock is a Hold with a Yen1750.00 price target. To see the full list of analyst forecasts on ONO Pharmaceutical Co stock, see the JP:4528 Stock Forecast page.
More about ONO Pharmaceutical Co
ONO Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company focused on the research, development and commercialization of prescription drugs. The firm operates under International Financial Reporting Standards (IFRS) and derives revenue from a portfolio of major products sold across multiple geographic regions.
Average Trading Volume: 2,011,348
Technical Sentiment Signal: Buy
Current Market Cap: Yen1087.5B
Learn more about 4528 stock on TipRanks’ Stock Analysis page.